|

Elranatamab Clinical Trials

26 actively recruiting trials across 14 locations

No change since June 2026

Also known as: Elranatamab-bcmm, Elrexfio, PF-0686313, PF-06863135, o PF-06863135 o ELREXFIO

Pipeline

Phase 1: 5Phase 2: 10Phase 3: 4Phase 4: 1Phase 1/2: 5

Top Sponsors

  • Pfizer5
  • Massachusetts General Hospital2
  • M.D. Anderson Cancer Center2
  • YOUNGIL KOH1
  • University of Miami1

Indications

  • Cancer26
  • Multiple Myeloma15
  • Relapsed Refractory Multiple Myeloma (RRMM)3
  • Relapse Multiple Myeloma2
  • Multiple Myeloma (MM)2

Other6 trials

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Phase 3
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/2
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Phase 2
The Norwegian Immunotherapy in Multiple Myeloma Study
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Phase 2

Boston, Massachusetts4 trials

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Beth Israel Deaconess Medical Center

Phase 1
ELISA in Relapsed/Refractory MM

Massachusetts General Hospital

Phase 2
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Dana-Farber Cancer Institute

Phase 1/2
Elranatamab in R/R Multiple Myeloma

Massachusetts General Hospital

Phase 2

Birmingham, Alabama3 trials

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1/2
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

University of Alabama at Birmingham

Phase 2

Houston, Texas2 trials

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

MD Anderson Cancer Center

Phase 2
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Gilbert, Arizona1 trial

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Banner MD Anderson Cancer Center

Phase 1

Clovis, California1 trial

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Clovis Community Medical Center

Phase 3

Duarte, California1 trial

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site

Phase 1/2

Irvine, California1 trial

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

UCI Health - Irvine Infusion Pharmacy ACC

Phase 4

La Jolla, California1 trial

Elranatamab in Relapsed/Refractory Multiple Myeloma

University of California San Diego

Phase 2

Coral Gables, Florida1 trial

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

Phase 1

Jupiter, Florida1 trial

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Jupiter Medical Center/Anderson Family Cancer Institute

Phase 3

Miami, Florida1 trial

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

University of Miami

Phase 2

Tampa, Florida1 trial

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Moffitt Cancer Center

Phase 2

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.